⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
WOCKPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.9
| Stock Code | WOCKPHARMA | Market Cap | 22,931 Cr. | Current Price | 1,413 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 163 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,385 ₹ | DMA 200 | 1,395 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 54.0 Cr. | PAT Prev Qtr | 69.0 Cr. |
| RSI | 54.1 | MACD | -10.0 | Volume | 8,54,933 | Avg Vol 1Wk | 5,18,440 |
| Low price | 1,110 ₹ | High price | 1,870 ₹ | PEG Ratio | 6.73 | Debt to equity | 0.76 |
| 52w Index | 39.9 % | Qtr Profit Var | 250 % | EPS | 8.68 ₹ | Industry PE | 29.1 |
📊 WOCKPHARMA shows weak-to-moderate potential for swing trading. While recent profit growth and strong price recovery provide some positives, high valuation, weak fundamentals, and bearish technical indicators limit upside. Entry is only advisable near strong support levels, while exits should be timed around resistance zones.
Positive ✅
- Quarterly profit variation (+250%) highlights strong recovery momentum despite lower absolute PAT.
- EPS of 8.68 ₹ supports earnings visibility.
- RSI at 54.1 indicates neutral-to-positive momentum.
- Stock trading near both 50 DMA (1,385 ₹) and 200 DMA (1,395 ₹), showing technical stability.
- Strong 52-week performance (+39.9%) highlights investor confidence.
- High trading volume (8.5 lakh) compared to weekly average, suggesting active market participation.
Limitation ⚠️
- Extremely high P/E ratio (163) compared to industry average (29.1), suggesting overvaluation.
- ROCE (4.40%) and ROE (-0.53%) reflect poor capital efficiency.
- PEG ratio of 6.73 indicates weak growth prospects relative to valuation.
- MACD (-10.0) signals bearish momentum.
- Debt-to-equity ratio of 0.76 indicates high leverage risk.
- No dividend yield, reducing shareholder returns.
Company Negative News ❌
- Quarterly PAT declined (54 Cr. vs 69 Cr.), showing earnings pressure despite variation improvement.
- Decline in both FII (-0.10%) and DII (-0.45%) holdings reflects reduced institutional confidence.
Company Positive News 🌟
- Strong quarterly profit variation (+250%) shows operational improvement.
- EPS of 8.68 ₹ provides earnings support.
Industry 📈
- Industry P/E at 29.1 is much lower, highlighting sector stability compared to WOCKPHARMA’s valuation.
- Pharmaceutical sector demand remains resilient with long-term growth potential.
Conclusion 📝
WOCKPHARMA is a risky swing trade candidate due to overvaluation and weak fundamentals. Optimal entry would be near 1,350–1,370 ₹ support if RSI holds steady. For existing holders, consider exiting around 1,500–1,550 ₹ (near resistance levels), as upside is capped by high debt, weak efficiency, and bearish momentum.